Tags: Drug.

Linifanib (ABT-869) is a structurally novel potent inhibitor of receptor tyrosine kinases (RTK) vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) with IC50 of 0.2 2 4 and 7 nM for human endothelial cells PDGF receptor beta (PDGFR-β) KDR and colony stimulating factor 1 receptor (CSF-1R) respectively. It has much less activity (IC50s > 1 μM) against unrelated RTKs soluble tyrosine kinases or serine/threonine kinases.

Linifanib_skeletal.svg
ATC prefix
None
CAS number
606143-52-6
FDA UNII code
CO93X137CW
IUPAC name
1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea
PubChem
11485656

Loading...

This page contains content from the copyrighted Wikipedia article "Linifanib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.